 HANGZHOU, China, March 16, 2021 PRNewswire -- WuXi Biologics WuXi Bio 2269.HK, a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China Pfizer to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China. The transaction is expected to close in the first half of 2021, which will immediately boost the commercial Drug Substance DS and Drug Product DP capacities for WuXi Biologics to address surging manufacturing demands. 